To develop a personalized treatment strategy, tumor tissues were embedded in paraffin and sent for genetic analysis, which detected mutations in the TP53 and STAG2 genes, with mutant allele frequencies of 31.62% and 3.17%, respectively. The gene discussed is TP53; the disease is neoplasm.